Overview
GoodRx provides coupons and price comparisons to help people save on prescription medications. Users search their drug on the site or app, compare prices at 70,000+ pharmacies, and redeem coupons at checkout; it also offers GoodRx Gold, a subscription with deeper discounts, and earns revenue from pharmacy referrals, advertising, and partnerships. It differentiates itself with a large pharmacy network, upfront price transparency, and a Gold membership for ongoing savings. Its goal is to make prescription medications more affordable and accessible while protecting user privacy and security.
Work here?Claim your company
About GoodRx
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Santa Monica, CA
Founded
2005
Get referred to GoodRx
See people who can refer or advise you
Simplify's take
What believers are saying
- Q2 2026 subscription revenue rose 39% to $28.5 million, with plans up 14%.
- Pharma Direct revenue jumped 76% in Q2 2026, driven by GLP-1 access.
- Employer Direct launched October 29, 2026, and Companion enters employer benefits in January 2027.
What critics are saying
- GoodRx faces a $32 million privacy settlement, with final approval due February 11, 2027.
- FTC penalties and data-sharing allegations make advertisers and partners distrust GoodRx's consumer platform.
- Prescription transactions revenue fell 26% in Q2 2026; core traffic erosion can cripple the business.
What makes GoodRx unique
- GoodRx owns consumer pharmacy pricing at 70,000 U.S. pharmacies and now Employer Direct.
- Companion launched May 2026, and Family Plan followed September 3, 2026.
- GoodRx now bundles prescriptions, telehealth, labs, dental, vision, and imaging.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.2B
Above
Industry Average
Funded Over
3 Rounds
Benefits
- Medical, dental, and vision insurance
- 401(k) with a company match
- ESPP
- Unlimited vacation
- "Take care of yourself" days
- 11 paid holidays
Stock Price
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Descope launches Envoy to let consumer apps accept personal AI agents as users. Customer and agentic identity platform company Descope Inc. today launched Envoy, a service that lets consumer websites and apps accept personal artificial intelligence agents acting for their customers without rebuilding how people sign in. Agents arriving through Envoy get an identity of their own, separate from the customer's. The launch goes after a choice consumer businesses have been stuck with since agents such as Meta Platforms Inc.'s Muse started shopping and paying for things on people's behalf. Amazon.com Inc. blocked Muse from its store in September, saying the agent did not identify itself as one when placing orders, and JPMorgan Chase & Co. moved a month later to keep outside agents away from customer bank accounts. Descope expects blocking will get harder to maintain as more customers do their shopping through an agent. The alternative, in Descope's telling, is an agent that signs in as the customer with the person's own password and one-time code. Nothing in that session shows software was involved, so when a fraud rule fires the logs point at the person. The business ends up absorbing the cost in disputed orders and returns. Envoy is built around a proposed standard that offers a third option. Meta and Sierra Technologies Inc. published a 0.1 draft of the Personal Agent Protocol in October to set rules for how an agent signs in for someone without posing as them. Under Poppy, as the draft is known, a business publishes the endpoints agents should use and verifies which agent is calling. The business then issues a session bound cryptographically to that agent until the interaction ends. Developers who adopt Envoy do not have to implement Poppy themselves or keep pace with revisions to it. Descope runs discovery and agent identification, and agents need no advance registration because each one presents a published client metadata document. Session tokens are tied to a key the agent holds through the Demonstrating Proof of Possession standard. Envoy supports all three of the draft's sign-in types. Inside Envoy, businesses spell out what an agent is allowed to do on a customer's account through the Rich Authorization Requests extension to OAuth. In the example Descope gives, a retailer could let a shopping agent place orders for a customer and still keep it away from the payment methods on file. How long any elevated access lasts is left to the retailer as well. Sensitive actions can go back to the customer for approval on a separate channel, using Client-Initiated Backchannel Authentication. Another example from Descope has an agent booking travel hold a fare it found overnight and send the details to the customer's phone for approval the next morning. Every token and log entry records the customer and the agent as separate parties, so a company can revoke an agent's access without signing the customer out. Envoy runs alongside whatever customer identity system a business already has. Descope co-founder and Chief Executive Slavik Markovich said every login page on the internet was built for a person on the other side, and "that assumption no longer holds true." In his view, the Personal Agent Protocol is doing for consumer agents what the Model Context Protocol did for enterprise tools. GoFundMe Inc. and GoodRx Holdings Inc. are among the launch and design partners working with Descope on Envoy over the coming months. Each donation on GoFundMe is "an act of trust," according to Arnie Katz, the fundraising platform's chief product and technology officer. He said Envoy will keep the donor and the agent distinct in every session and ask users to approve donations from their phones. At GoodRx, Chief Technology Officer Nitin Shingate expects people to send agents out to compare pharmacies and find the lowest price on a prescription before they reach the counter. Agents there will get limited permissions covering pricing information. Agent builders get a tool of their own. A Poppy software development kit, released alongside Envoy, lets any agent work with the protocol, with Descope handling discovery and session management behind it. The kit is written in TypeScript and has no external dependencies. Envoy sits on top of Descope's Agentic Identity Hub, which the company updated last month with controls aimed at agents employees build or adopt inside their own organizations. The hub now handles authentication and access control for more than 1,000 MCP servers and millions of agent transactions each month, according to Descope. Descope is a venture capital-backed startup whose investors include Lightspeed Venture Partners, Notable Capital and Dell Technologies Capital. The company has raised $88 million to date, including a $35 million seed extension in September 2025. Image: Descope. A message from John Furrier, co-founder of SiliconANGLE: Support its mission to keep content open and free by engaging with theCUBE community. Join theCUBE's Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities. * 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more * 11.4k+ theCUBE alumni - Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network Are you an AWS customer? Support SiliconANGLE financially by buying your AWS services from its Marketplace portal page and links: https://siliconangle.com/aws-marketplace/. About SiliconANGLE Media. SiliconANGLE Media is a recognized leader in digital media innovation, uniting breakthrough technology, strategic insights and real-time audience engagement. As the parent company of SiliconANGLE, theCUBE Network, theCUBE Research, CUBE365, theCUBE AI and theCUBE SuperStudios - with flagship locations in Silicon Valley and the New York Stock Exchange - SiliconANGLE Media operates at the intersection of media, technology and AI. Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Its new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.
GoodRx expands Companion membership to families and pets. GoodRx is expanding Companion, the paid membership it is making central to its subscription strategy, from an individual product to a family plan that can also include pets. Companion is a prescription and healthcare discount membership. It is not health insurance. GoodRx launched the Companion Family Plan on September 3 for $24.99 per month, or $16.99 per month when paid annually. A primary member can add up to four dependents, including children, adult family members and pets. There are no age restrictions for human dependents. The individual Companion membership, introduced in May, costs $14.99 per month or the equivalent of $9.99 per month when paid annually. For monthly subscribers, moving to the Family Plan costs another $10 and can extend access to four additional family members or pets. For annual subscribers, the difference is $7 per month on an equivalent monthly basis. GoodRx said at launch that Companion Family provides access to more than 250 eligible generic medications at no additional cost, with hundreds of additional medications available for less than $10. The company also offers discounts on services including dental, vision, lab and imaging. The benefits aren't identical for everyone on the plan. Under GoodRx's terms, add-on family members don't receive discounted telehealth services. Pets can receive prescription savings but don't receive telehealth or discounts for healthcare services such as dental and vision. Some benefits, including discounted online care, remain with the primary member. Availability can also vary by location. Companion is not currently available in Washington state, and some healthcare benefits vary by state. GoodRx plans to offer Companion through its Employer Direct business beginning in 2027. Employers will be able to subsidize some or all of the membership cost, opening another path for GoodRx to reach members beyond direct consumer acquisition. The Family Plan arrives as subscriptions take a larger role in GoodRx's business. Subscription revenue increased 39% to $28.5 million in the second quarter, and GoodRx ended June with 764,000 subscription plans, up from 668,000 a year earlier. Subscription Insider reported in August that GoodRx was shifting more product and marketing investment toward subscriptions and making Companion its primary subscription offering. Family memberships themselves aren't new to GoodRx. GoodRx Gold and RxSmartSaver+ already allow multiple members on some plans. What's new is the expansion of Companion, the product GoodRx is now putting at the center of its subscription strategy. Insider take. GoodRx gives subscription operators a useful example of what changes when one paying customer can extend a membership to more of the family. The customer math is easy to see. Pay more each month and several people or pets can find value in the same membership. The operator math is harder. More covered members could make Companion harder to cancel because its value is spread across the family. But those additional members can also use more benefits, which may make the plan more expensive to serve. GoodRx has made choices about that tradeoff. Some benefits can be shared. Others stay with the primary member, and pets receive a narrower set of benefits. That's the part operators should watch. Expanding a membership isn't only about how many people can join. It's also about deciding which benefits can travel with them and which should remain limited. Subscription Insider won't know yet whether GoodRx got that balance right. The useful numbers will come later: how many individual members move to Family, how much the added benefits get used and whether those families stay longer. The test is whether broader access makes the membership more valuable to keep without making it too expensive to serve. Related Member Resource If you're considering adding or expanding a paid membership inside a larger business, this resource helps you work through what changes across customer value, revenue, renewal, and the economics of the broader business. It includes a transition scorecard to help you assess the shift.
GoodRx expands subscription strategy with Companion Family Plan. New $24.99 monthly plan includes a primary member and up to four dependents, including children, adults, and pets, with more than 250 generic medications available for free and savings on dental, vision, lab and imaging services. September 3, 2026. 9:17 AM SANTA MONICA, Calif. - GoodRx today launched the Companion Family Plan, expanding its everyday healthcare subscription to entire households, including children, adult family members, and pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion's free and low-cost prescriptions and savings on common healthcare services together in one affordable, predictably priced membership. "Families don't experience healthcare costs one person at a time. They're simultaneously managing prescriptions and care for kids, parents, partners, and even pets," said Wendy Barnes, President and CEO of GoodRx. "Expanding Companion across the entire household allows us to support consumers in a way that reflects this reality. It also advances our strategy to make GoodRx a more central part of how consumers navigate and pay for healthcare." One Plan. More Ways for Families to Save. The Companion Family Plan, which costs $24.99 per month or $16.99 per month when paying annually, extends Companion benefits to a primary member and up to four dependents, which may include children, adult family members, and pets. Members can access more than 250 eligible generic medications for free and hundreds more for under $10 at nearly every pharmacy nationwide, plus savings on dental, vision, lab and imaging services. The primary member also receives access to $19 online care visits. Together, these features give families an affordable and predictable way to save across prescriptions and common healthcare needs. Building a Broader Subscription Offering The Companion Family Plan expands the reach and value of GoodRx's subscription offering, creating a more continuous way to support consumers beyond individual prescription transactions. Building on more than a decade of medication pricing expertise, extensive relationships with retail pharmacies, and a trusted consumer brand, GoodRx is uniquely positioned to scale this model. Companion complements the company's condition-focused offerings for weight loss, erectile dysfunction, and hair loss. Supporting Growth and Retention for Retail Pharmacy Partners Companion gives members access to meaningfully lower prices than they would receive through a traditional prescription discount, while allowing them to continue filling at the pharmacies they already know and trust. This helps retail pharmacy partners strengthen patient relationships, support prescription volume, and deliver a more compelling consumer experience, with no additional cost to participate. The Companion Family Plan broadens those benefits while preserving favorable pharmacy economics and reinforcing the value of GoodRx's retail pharmacy network. Making Companion an Employee Benefit GoodRx plans to offer Companion through Employer Direct, giving employers a flexible, predictable way to subsidize memberships and help lower employees' out-of-pocket healthcare costs. Companion can complement existing health benefits by addressing prescription costs and other coverage gaps, or extend healthcare savings to workers who are not eligible for traditional benefits. The expansion creates a new channel for Companion while giving employers another way to support healthcare affordability for their workforce. Get the latest Chain Drug Review news delivered straight to your inbox. Have news to share? Send Chain Drug Review your press releases and announcements.
GoodRx (NASDAQ:GDRX) major shareholder sells $437,819.12 in stock. August 26, 2026 Key points. * Francisco Partners IV sold 127,273 GoodRx shares for $437,819 at an average price of $3.44, reducing its ownership by 16.51% to 643,466 shares. The shareholder also sold more than 2.6 million additional shares in transactions from August 19-26. * GoodRx shares rose 5.2% to $3.65, giving the company a market capitalization of approximately $1.25 billion. Its latest quarterly results matched earnings expectations at $0.08 per share and exceeded revenue estimates, although revenue declined 1.3% year over year. * Analyst sentiment remains mixed, with four Buy, six Hold and three Sell ratings and a consensus price target of $4.23. Recent target changes included UBS raising its target to $3.75 and Citigroup increasing its target to $5.00. * Interested in GoodRx? Here are five stocks we like better. GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $3.44, for a total value of $437,819.12. Following the completion of the transaction, the insider directly owned 643,466 shares of the company's stock, valued at approximately $2,213,523.04. This trade represents a 16.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC. Francisco Partners Iv, L.P. also recently made the following trade(s): * On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. * On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The shares were sold at an average price of $3.46, for a total value of $496,835.24. * On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50. * On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68. * On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75. GoodRx stock up 5.2%. NASDAQ:GDRX traded up $0.18 during trading hours on Wednesday, reaching $3.65. The company had a trading volume of 3,534,816 shares, compared to its average volume of 1,909,305. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60. The business's 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $2.66. Discover more Integrated Circuits Stock Screener Tool Financial Markets News GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.09 earnings per share. On average, equities analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year. Analyst ratings changes. A number of research firms recently weighed in on GDRX. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. UBS Group upped their target price on GoodRx from $2.50 to $3.75 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Citigroup lifted their price target on shares of GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, GoodRx has an average rating of "Hold" and a consensus target price of $4.23. Institutional inflows and outflows. A number of large investors have recently modified their holdings of the stock. Lazard Asset Management LLC grew its holdings in GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after buying an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP lifted its stake in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company's stock valued at $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its stake in GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company's stock valued at $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP purchased a new position in GoodRx during the 3rd quarter worth $33,000. Institutional investors own 63.77% of the company's stock. About GoodRx. GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
GoodRx reported second-quarter revenues of $200.4 million, down 1.3% year-on-year but exceeding analyst expectations by 3.5%. The prescription drug price comparison platform delivered the slowest revenue growth among seven healthcare technology stocks tracked in the analysis. Despite the modest performance, GoodRx provided strong forward guidance. Its full-year revenue and EBITDA forecasts both topped analyst expectations. The stock has responded positively, rising 14.1% since the earnings announcement and currently trading at $3.73. The company, founded in 2011, helps consumers find lower prescription medication prices through comparison tools and discount codes. The healthcare technology sector as a group reported strong results, with revenues beating consensus estimates by 3.7% and next quarter guidance exceeding expectations by 2.8%. Share prices across the sector have risen 6.8% on average following the latest earnings.
GoodRx is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About GoodRx
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Santa Monica, CA
Founded
2005
GoodRx is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs